IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

28 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Completes A$80 Million Capital Raise

27 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

27 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

20 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep to Participate at the Jefferies Healthcare Conference

07 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

05 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

02 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

29 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

26 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

25 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

24 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

17 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

16 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep to Participate in the JMP Securities Life Sciences Conference

09 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

02 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

01 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

27 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

26 Apr 2023 10:00:00 By Nasdaq GlobeNewswire

Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

26 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

17 Apr 2023 09:00:00 By Nasdaq GlobeNewswire